Penciclovir
- CAS No.
- 39809-25-1
- Chemical Name:
- Penciclovir
- Synonyms
- PCV;CL200;VSA 671;Vectavir;BRL-39123;BRL-39123A;Penciceovir;PENCICLOVIR;PENCICLOVIR-D4;Penciclovir >
- CBNumber:
- CB7731886
- Molecular Formula:
- C10H15N5O3
- Molecular Weight:
- 253.26
- MOL File:
- 39809-25-1.mol
- MSDS File:
- SDS
- Modify Date:
- 2024/5/6 14:49:57
| Melting point | 275-277°C |
|---|---|
| Boiling point | 653.4±65.0 °C(Predicted) |
| Density | 1.68±0.1 g/cm3(Predicted) |
| storage temp. | Keep in dark place,Sealed in dry,Store in freezer, under -20°C |
| solubility | 0.02 M potassium phosphate: soluble2mg/mL |
| pka | 14.42±0.10(Predicted) |
| form | White solid |
| color | White to Off-White |
| λmax | 253nm(H2O)(lit.) |
| Merck | 14,7083 |
| CAS DataBase Reference | 39809-25-1(CAS DataBase Reference) |
| EPA Substance Registry System | 6H-Purin-6-one, 2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)butyl]- (39809-25-1) |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |   GHS07,GHS02 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Danger | |||||||||
| Hazard statements | H315-H319-H225 | |||||||||
| Precautionary statements | P501-P240-P210-P233-P243-P241-P242-P264-P280-P370+P378-P337+P313-P305+P351+P338-P362+P364-P303+P361+P353-P332+P313-P403+P235 | |||||||||
| Hazard Codes | Xi | |||||||||
| Risk Statements | 36 | |||||||||
| Safety Statements | 26 | |||||||||
| WGK Germany | 3 | |||||||||
| RTECS | UP0789400 | |||||||||
| HS Code | 2933.99.8290 | |||||||||
| NFPA 704 |
|
Penciclovir price More Price(3)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Sigma-Aldrich(India) | P0035 | Penciclovir | 39809-25-1 | 100MG | ₹16389.05 | 2022-06-14 | Buy |
| TCI Chemicals (India) | P2164 | Penciclovir | 39809-25-1 | 200MG | ₹11500 | 2022-05-26 | Buy |
| TCI Chemicals (India) | P2164 | Penciclovir | 39809-25-1 | 1G | ₹13900 | 2022-05-26 | Buy |
Penciclovir Chemical Properties,Uses,Production
Description
Vectavir was launched in the UK for herpes labialis. Penciclovir is synthetically available by two routes of four steps each from 2- (hydroxymethyl)butane-l,4-diol and is active against HSV-1, HSV-2 VZV but has limited activity against CMV. Vectavir is an acyclic guanosine analog that acts as a competitive inhibitor of DNA polymerase. It is a metabolic product of famcyclovir that is preferentially phosphorylated by viral infected cells (by thymidine kinases) over normal cells. The triphosphate has a low activity against cellular DNA polymerase which is one possible explanation for its low toxicity. While its spectrum of activity is similar to acyclovir, it is longer acting because its triphosphate is 20 times more stable and is not metabolized.
Chemical Properties
White Cyrstalline Solid
Uses
A deuterated version of Penciclovir, an antiviral
Indications
Penciclovir has activity against HSV-1, HSV-2, VZV, and HBV. After oral administration, famciclovir is converted to penciclovir by first-pass metabolism. Penciclovir has a mechanism of action similar to that of acyclovir. It is first monophosphorylated by viral thymidine kinase; then it is converted to a triphosphate by cellular kinases.
Definition
ChEBI: A member of the class of 2-aminopurines that is guanine in which the hydrogen at position 9 is substituted by a 4-hydroxy-3-(hydroxymethyl)but-1-yl group. An antiviral drug, it is administered topically for treatment of herpes labialis. A prodrug, famciclo ir, is used for oral administration.
Acquired resistance
Penciclovir is inactive against thymidine kinase-deficient strains of HSV.
Pharmaceutical Applications
A synthetic acyclic purine nucleoside analog, usually administered orally as the diacetyl ester, famciclovir, which acts as a prodrug undergoing rapid first-pass metabolism to release the active compound in vivo. The parent compound has virtually no oral bioavailability, but is supplied as a topical formulation.
Pharmacokinetics
Oral absorption, penciclovir： 5%
famciclovir： 77%
Cmax famciclovir 250 mg oral： 1.6 mg/L after 0.5–1.5 h
famciclovir 500 mg oral： 3.3 mg/L after 0.5–1.5 h
famciclovir 750 mg oral： 5.1 mg/L after 0.5–1.5 h
Plasma half-life： 2.1–2.7 h
Volume of distribution： c. 1.5 L/kg
Plasma protein binding： <20%
Following absorption famciclovir is converted rapidly by
enzyme-mediated deacetylation and oxidation to penciclovir.
Food does not lead to any significant change in the availability
or elimination.
The pharmacokinetics in elderly subjects are similar to
those seen in younger subjects, although small increases in
AUC and plasma half-lives were seen, consistent with slightly
decreased renal clearance.
Renal excretion is the major route of elimination, 50–60%
of an oral dose being recovered in the urine. After intravenous
infusion, about 70% is excreted unchanged in the urine.
After oral administration of famciclovir, penciclovir accounts
for 82% of urinary drug-related material. The remainder
includes metabolites, of which the largest is the 6-deoxy precursor
of penciclovir. Renal clearance exceeds glomerular filtration,
indicating renal tubular secretion.
Clinical Use
Penciclovir is approved as a topical formulation for the treatment of herpes labialis. In immunocompetent individuals, penciclovir shortens the duration of lesion presence and pain by approximately half a day when it is initiated within an hour of lesion development and applied every 2 hours during waking hours for 4 days.
Side effects
In clinical trials the incidence of adverse events after famciclovir, aciclovir and placebo were similar, the most common adverse events being headache and nausea.
Penciclovir Preparation Products And Raw materials
Raw materials
1of3
chevron_rightPreparation Products
| Supplier | Tel | Country | ProdList | Advantage | Inquiry |
|---|---|---|---|---|---|
| Alembic Pharmaceuticals Limited | +91-2652280880 +91-2652280550 | Gujarat, India | 115 | 58 | Inquiry |
| Narmada Organics | +91-9601758907 +91-9409133000 | Gujarat, India | 19 | 58 | Inquiry |
| Rivashaa Agrotech Biopharma Pvt. Ltd. | +91-26463395 +91-7926462688 | Gujarat, India | 1615 | 58 | Inquiry |
| Maithri Drugs Pvt Ltd | +91-9059204566 +91-9848881740 | Telangana, India | 64 | 58 | Inquiry |
| TORRENT PHARMACEUTICALS LTD | +91-79-26599000 | New Delhi, India | 36 | 58 | Inquiry |
| Euroasia Trans Continental | +91 22 56349035-36 | New Delhi, India | 519 | 47 | Inquiry |
| CLEANCHEM LABORATORIES LLP | +91 98921 69560 | New Delhi, India | 326 | 58 | Inquiry |
| API Pharma Tech | 91-40-40172171 | Hyderabad, India | 7 | 58 | Inquiry |
| Indogulf Group | 91-22-23455220 | Maharashtra, India | 249 | 58 | Inquiry |
| SynZeal Research Pvt Ltd | +1 226-802-2078 | Gujarat, India | 6522 | 58 | Inquiry |
39809-25-1(Penciclovir)Related Search:
1of4
chevron_right